Why Choose Masimo?

Masimo pioneered motion and low perfusion tolerant technology. Masimo SET is the technology proven clinically in over 100 studies since 1994. Masimo Signal Extraction Technology (SET) is a breakthrough technology that represents a new and fundamentally distinct method of acquiring, processing and reporting arterial oxygen saturation and pulse rate. Masimo SET greatly enhances the accuracy of SpO2 monitoring, particularly in the most difficult patient conditions such as motion and low peripheral perfusion.

Numerous clinical studies have demonstrated that the use of Masimo SET, in conjunction with Masimo’s sensors, significantly:

  1. Reduce the cost of care
  2. Improve patient care
  3. Improve patient safety

Clinically Proven:

Over 100 independent and objective studies have shown that Masimo SET is the industry leading technology for pulse oximetry. In addition, two ECRI publications have focused on Masimo SET.

Maximum Accuracy, Lowest Cost, Guaranteed:

Only Masimo SET has the ability to give you accurate pulse oximetry when you need it most with a written guarantee to reduce your annual pulse oximetry costs.

The First and the Best Read-Through-Motion & Low Perfusion Pulse Oximeter:

  1. Unprecedented specificity and sensitivity. Essentially eliminates false alarms and detects virtually all true alarms.
  2. Accurate during most patient movement, including shivering, combativeness, neonatal movement, and seizures.
  3. Effective during helicopter and ambulance transport.
  4. Accurate during low perfusion.
  5. Designed to be accurate in intense ambient light and with electromagnetic interference, such as electrocautery.
  6. Reduces cost of care through reliable monitoring and durable adhesive sensors. Studies have shown that Masimo SET adhesive sensors are replaced less than half as often as other leading brands.
  7. Helps reduce neonatal eye damage. Two ground-breaking studies have shown that Masimo SET was an instrumental part of the protocol that dramatically reduced Retinopathy of Prematurity.1,2
  8. Accuracy and reliability of Masimo SET has, for the first time, made pulse oximetry a clinically useful diagnostic tool, helping clinicians determine severity of numerous patient iillnesses, including giving them the the ability to accurately diagnose congenital heart disease (CHD) in infants.3,4,5,6
  9. Reduces medical errors. Another ground-breaking study showed that Masimo SET helped reduce unnecessary ABG and excessive or precipitous oxygen use. In addition, it stated that Masimo reduces latent conditions, which have been linked to medical errors.7
  10. Proven most accurate SpO2 technology on cyanotic patients.8,9
  11. Masimo SET in FastSat mode tracks rapid changes in arterial O2 with high fidelity unike any other pulse oximeter, without false alarms.
  12. Masimo SET is considered the gold standard and has won more than twenty prestigious industry awards, including the Society for Technology in Anesthesia Outstanding Technology Award, the Society for Critical Care Medicine Technology Excellence Award, the Medical Device Manufacturing Design Award, the American Electronic Association Breakthrough Technology Award, the Frost & Sullivan New Standard of Care Award, and the Audie Lewis Award for the best technology and service among pulse oximetry vendors.

Signal Extraction Technology

Masimo SET technology enables the power of adaptive filters to be applied to real-time physiologic monitoring by utilizing proprietary techniques to accurately establish a “noise reference” in the detected physiologic signal, thus enabling direct calculation of arterial saturation and pulse rate. While other pulse oximetry technologies employ one, or sometimes two algorithms to attempt to measure a patient’s arterial oxygen saturation, Masimo SET’s unique patented approach employs five algorithms, working in parallel, to ensure continuous, accurate SpO2 measurement, even under the most challenging conditions.

  • 1 Chow L, Wright K, Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight Infants? Pediatrics 2003; 111(2):339-345.
  • 2 Sola A, Rogido MR, Deulofeut R. Oxygen as a neonatal health hazard: call for detente in clinical practice. Acta Paediatr. 2007;96:801-12.
  • 3 Gianelli A.D., Mellander M, Sunnegardh J, Sandberg K, Ostman-Smith I. Screening for duct-dependent congenital heart disease with pulse oximetry: A critical evaluation of strategies to maximize sensitivity, Acta Paediatrica, 2005; 94: 1590-1596.
  • 4 Toda Y, Takeuchi M, Iwasaki T, Shimizu K, Morita K. The Accuracy of Masimo SET and Nellcor N-595 in children with cyanotic congenital heart disease. Anesthesiology 2006; 105:A1704.
  • 5 Whitney GM, Tucker LR, Hall SR, Chang AC. Clinical evaluation of the accuracy of Masimo SET and Nellcor N-595 oximeters in children with cyanotic congenital heart disease. Anesthesiology 2005; 103:A1344.
  • 6 de-Wahl Granelli A., Östman-Smith I. Noninvasive peripheral perfusion index as a possible tool for screening for critical left heart obstruction. Acta Paediatrica. 2007; 96: 1455-1459.
  • 7 Durbin CG, Rostow SK. More reliable oximetry reduces the frequency of arterial blood gas analyses and hastens oxygen weaning after cardiac surgery. Crit Care Med. 2002;30(8):1735-1740.
  • 8 Tsutumi T, Nakashima M, Yasunaga H, Nakao F, Takamatsu J. Clinical evaluation of accuracy of Masimo LNOP Blue sensor in cyanotic infants. Crit Care Med. 2006;34(12):A56.
  • 9 Whitney GM, Tucker LR, Hall SR, Chang AC. Clinical evaluation of the accuracy of Masimo SET and Nellcor N-595 oximeters in children with cyanotic congenital heart disease. Anesthesiology. 2005;103:A1344.